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Connexin (Cx) makes up a type of intercellular channel called gap junction (GJ). GJ plays a regulatory role
in cellular physiology. The Cx expression level is often decreased in cancer cells compared to that in
healthy ones, and the restoration of its expression has been shown to exert antiproliferative effects. This
work aims to evaluate the effect of the restoration of connexin 43 (Cx43) (the most ubiquitous Cx
subtype) expression on sunitinib (SU)-induced cytotoxicity in malignant mesothelioma (MM) cells.
Increased Cx43 expression in an MM cell line (H28) improved the ability of SU to inhibit receptor
tyrosine kinase (RTK) signaling. Moreover, higher Cx43 expression promoted SU-induced apoptosis. The
cell viability test revealed that Cx43 enhanced the cytotoxic effect of SU in a GJ-independent manner. The
effect of Cx43 on a proapoptotic factor, Bax, was then investigated. The interaction between Cx43 and Bax
was conﬁrmed by immunoprecipitation. Furthermore, higher Cx43 expression increased the production
of a cleaved (active) form of Bax during SU-induced apoptosis with no alteration in total Bax expression.
These ﬁndings indicate that Cx43 most likely increases sensitivity to SU in H28 through direct interaction
with Bax. In conclusion, we found that Cx43 overcame the chemoresistance of MM cells.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Malignant mesothelioma (MM) is an aggressive tumor arising
from mesothelial cells. The main risk factor is asbestos. MM dis-
plays a long latency period that can take up to 40 years to develop
following the ﬁrst exposure to asbestos (1). Although it is a rare
tumor at present, it is becoming more common worldwide (2). For
example, the incidence of MM is now 2000e3000 per year in the
United States, and approximately 70,000 new MM cases are ex-
pected over the next 20 years (3). In Europe, the peak year of MM
incidence is expected to fall between 2015 and 2020, with an
estimated 250,000 new cases over the next 40 years (3). Surgery is
recommended for patients in clinical stage I; however, majority of
patients are diagnosed in an advanced stage, and surgery is not
suitable for them (4). Thus, systemic therapy is the only treatmentrmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).option for these patients. Unfortunately, MM is usually a chemo and
radioresistant tumor, which contributes to its poor prognosis (4).
The combination of pemetrexed and cisplatin is the only FDA-
approved regimen for MM, and its impact on the survival of pa-
tients is modest (5). No agents have shown an improvement in
survival as a second line therapy; therefore, new therapeutic stra-
tegies for the treatment of MM need to be established.
With a view to overcoming the chemoresistance of MM, we
turned our attention to connexin (Cx). Cx is a four-transmembrane
protein, and forms an intercellular channel called gap junction (GJ).
Cellular homeostasis, cell growth, and cell differentiation are
mediated via GJ intercellular communication (GJIC) (6). GJ allows
the direct transfer of several second messengers and small mole-
cules between apposed cells, including Ca2þ, cyclic AMP (cAMP),
cGMP, inositol 1,4,5-triphosphate (IP3), and glutathione (7). It has
been frequently observed that GJIC is aberrant, and Cx expression is
decreased in many cancer cells (8). Many Cx gene transfection ex-
periments have suggested that Cx-mediated GJIC works as a tumor
suppressor in cells that originate in tissues in which it is normallynese Pharmacological Society. This is an open access article under the CC BY-NC-ND
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e2618expressed (9). Recently, it has also been shown that connexin 43
(Cx43) could reduce cell growth in the absence of GJIC (10).
Therefore, Cx exerts a tumor suppressive effect through both, GJ-
dependent and GJ-independent mechanisms. We have previously
shown that Cx43, the major Cx subtype in mesothelial cells, en-
hances cisplatin-induced cytotoxicity in MM cells in a GJ-
independent manner (11).
Although the platinum-based chemotherapy has been mainly
used for the MM patients at present, the identiﬁcation of key
growth factors, glycoproteins, and genetic mutations in MM
tumorigenesis have generated interest in the development of new
agents to target these oncogenic abnormalities (1). Vascular
endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) have been reported to play an important role in the
growth of MM cells via autocrine loops (12,13). Moreover, it has also
been shown that VEGF expressionwas higher in MM tissues than in
healthy ones, with a correlation between higher VEGF expression
level and worse prognosis (14). Based on these observations, it is
rational to target the signaling pathways stimulated by these
growth factors.
Sunitinib (SU) is a multi-targeted tyrosine kinase inhibitor (TKI),
which suppresses the activation of VEGF receptors (VEGFRs 1e3),
PDGF receptors (PDGFRs a and b), and other growth factor re-
ceptors (15). It is approved for the treatment of advanced renal cell
carcinoma, imatinib-resistant or intolerant gastrointestinal stromal
tumors, and advanced pancreatic neuroendocrine tumors (15,16).
Recently, its antitumor activity was investigated in patients with
other solid malignancies such as breast cancer (17), glioblastoma
(18), and MM (19,20). However, SU displayed a limited activity in
these patients. Therefore, there is a need for investigation into
methods for making SUmore appropriate as a therapeutic agent for
these tumors, including MM.
Based on these facts, this report describes the effect of increased
Cx43 expression on SU-induced cytotoxicity in MM cells.
2. Materials and methods
2.1. Reagents
All cultures and reagents were purchased from Sigma (St. Louis,
MO, USA) unless otherwise indicated. Sunitinib malate (SU) was
dissolved in dimethyl sulfoxide (DMSO; Wako Pure Chemicals,
Osaka) at a concentration of 10 mM and stored at 20 C. A GJ
inhibitor, 18b-glycyrrhetinic acid (GA), was dissolved in DMSO at a
concentration of 40 mM and stored at 20 C. 6-
Carboxyﬂuorescein (6-CF) was dissolved in distilled water at a
concentration of 10 mg/mL and stored at 4 C. Dextran tetrame-
thylrhodamine (DTMR; Invitrogen, Carlsbad, CA, USA) was dis-
solved in distilled water at a concentration of 50 mg/mL and stored
at 20 C. 3-(4,5-Dimetylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT; Dojindo Laboratories, Kumamoto) was dissolved
in distilled water at a concentration of 5 mg/mL and stored
at 20 C.
2.2. Cell culture, construct creation, and transfection
H28, a representative human MM cell line, was obtained from
ATCC (Manassas, VA, USA) and grown in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum (FBS), 100 units/mL peni-
cillin/100 mg/mL streptomycin, 0.01 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer solution, 1 mM so-
dium pyruvate, and 2.5 g/L D-glucose at 37 C in 5% CO2. All sup-
plements were purchased from Gibco (Palo Alto, CA, USA) except
for FBS (Biowest, Kansas City, MO, USA). Cx43-transfected H28 cells
(H28-T) were produced as previously described (11). At that time,control vector-transfected cells (H28-W) were also produced, and
we have conﬁrmed that H28-W and H28 cells have the same level
of Cx43 mRNA and protein expression and GJ function. Therefore,
H28 and H28-T cells were used in this study.2.3. Real-time polymerase chain reaction (PCR) analysis
Total RNA was isolated using a ChargeSwitch® Total RNA Cell
Kits (Invitrogen), and cDNAwas synthesized using a Super Script™
RNase H Reverse Transcriptase (Invitrogen). Real-time PCR was
performed using an ABI StepOne™ Real-time PCR System (Applied
Biosystems Japan Ltd., Tokyo) and SYBR® Premix Ex Taq™ (Takara
Bio Inc., Shiga). The following primers were used: RPL32 [accession
number (NM_000994)] sense (nucleotides-CATCTCCTTCTCGG-
CATCA) and anti-sense (nucleotides-AACCCTGTTGTCAATGCCTC);
Cx43 [accession number (NM_000165)] sense (nucleotides-ACT-
CAACTGCTGGAGGGAAG) and anti-sense (nucleotides-GCACATGA-
GAGATTGGGAAA). The PCR reactionwas performed at 95 C for 10 s
followed by 40 cycles at 95 C for 5 s and 60 C for 31 s. All datawere
normalized to the internal standard RPL32.2.4. Immunoprecipitation and western blot analysis
A total of 1.5  105 H28 cells and 3.0  105 H28-T cells were
seeded in 60 mm dishes. After 6 h incubation, the cells were
cultured in 0.1% FBS medium for 24 h followed by treatment with
10 mM SU for each indicated period. Control cells were treated
with 0.1% DMSO. Cells were collected by scraping and dissolved in
ice-cold lysis buffer [50 mM Tris (pH 7.4) (Invitrogen), 150 mM
sodium chloride (NaCl) (Wako Pure Chemicals), 1% Triton X (Wako
Pure Chemicals), 10 mM b-glycerophosphate, 1 mM sodium
orthovanadate, 1 mM ethylenediaminetetraacetic acid (Dojindo
Laboratories), 1 mM phenylmethane sulfonyl ﬂuoride, and 1%
protease inhibitor cocktail]. Protein concentrations were deter-
mined by using a DC protein assay kit (Bio-Rad, Tokyo). For
immunoprecipitation, total cell lysates (100 mg) pre-cleared with
protein sepharose G (GE Healthcare, Buckinghamshire, UK) for 1 h
at 4 C, were immunoprecipitated with 3.2 mg anti-Cx43 antibody,
1 mg anti-Bax antibody or anti-rabbit antibody (negative control)
for 1 h at 4 C followed by incubation with protein sepharose G for
1 h at 4 C. Immunoprecipitates were washed 5 times with lysis
buffer followed by resuspension in sample buffer [250 mM Tris
(pH 6.8), 40% sucrose (Wako Pure Chemicals), 20% 2-
mercaptoethanol (Wako Pure Chemicals), 8% sodium dodecyl
sulfate (SDS) (Wako Pure Chemicals), and 0.002% bromophenol
blue (ICN Biomedicals, Eschwege, Germany)] and boiling for 5 min
at 100 C. Then, immunoprecipitates were puriﬁed by centrifu-
gation at 2300 g. For western blotting, total cell lysates (10 mg or
25 mg) or 5 mL of immunoprecipitates were separated using a 7.5%,
10% or 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
gel. 30% Acrylamide solution was purchased from Bio-Rad. The
separated proteins were then transferred to a polyvinylidene
diﬂuoride membrane (ATTO, Tokyo). After that, the membranes
were blocked with 5% skim milk (Megmilk Snow Brand, Co., Ltd.,
Tokyo) in tris-buffered saline and tween 20 (TBS-T) [13.7 mM NaCl,
25 mM Tris, and 0.05% Tween 20 (Wako Pure Chemicals)] or 5%
bovine serum albumin (BSA) in TBS-T for 1 h at room temperature
or overnight at 4 C. The membranes were then incubated with
primary antibodies for 1 h at room temperature or overnight at
4 C followed by incubation with secondary horse radish peroxi-
dase (HRP)-conjugated antibodies for 1 h at room temperature.
The primary antibodies are shown in Table 1. The detection was
accomplished using an Immobilon™ Western Chemiluminescent
HRP Substrate (Merck Millipore, Darmstadt, Germany) and an
Table 1
The primary antibodies used in western blot analysis.
Target Source Cat. No. Dilution TBS-T with Incubation Species
Connexin 43 Sigma C6219 10000 1% skim milk 1 h, rt rabbit
VEGFR2 Cell Signaling Technologies
(Danvers, MA, USA)
#2479 1000 5% BSA on, 4 C rabbit
PDGFRb Santa Cruz Biotechnology
(Santa Cruz, CA, USA)
sc-53872 1000 5% BSA on, 4 C mouse
p44/42 MAPK (Erk1/2) (137F5): ERK Cell Signaling Technologies #4695 5000 1% skim milk on, 4 C rabbit
Phopho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204): p-ERK
Cell Signaling Technologies #9101 2000 5% BSA on, 4 C rabbit
Akt (pan) (C67E7): Akt Cell Signaling Technologies #4691 5000 1% skim milk on, 4 C rabbit
Phopho-Akt (Ser473): p-Akt Cell Signaling Technologies #9271 2000 5% BSA on, 4 C rabbit
Bax(N-20) Santa Cruz Biotechnology sc-493 10000 or 2000 (IP) 1% skim milk 1 h, rt or on, 4 C (IP) rabbit
b-actin Sigma A5441 10000 1% skim milk 1 h, rt mouse
VEGFR2: vascular endothelial growth factor receptor 2; PDGFRb: platelet-derived growth factor receptor b; MAPK: mitogen-activated protein kinases; Erk1/2: extracellular
signal-regulated kinases 1 and 2; BSA: bovine serum albumin; TBS-T; tris-buffered saline and tween 20; rt: room temperature; on: overnight; IP: immunoprecipitation.
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e26 19ImageQuant™ LAS 4000 (GE Healthcare). b-Actin was used as the
internal standard.2.5. Scrape loading and dye transfer assay
A total of 5.0  105 H28 cells and 1.0  106 H28-T cells were
seeded in 35mmdishes. After 24 h incubation, the cells were rinsed
twice with calcium-free phosphate buffered saline [PBS (); Nissui
Pharmaceutical Co., Ltd., Tokyo]. PBS () containing 0.05% 6-CF (a
GJ-permeable ﬂuorescent dye) and 0.05% DTMR (a GJ-impermeable
ﬂuorescent dye) was then added to the cells just before scrape at
room temperature. The dye solution was left on the cells for 3 min,
after which it was discarded, and the cells were rinsed 3 times with
PBS with calcium [PBS (þ)]. After that, the cells were ﬁxed with 4%
paraformaldehyde phosphate buffer solution (Wako Pure Chem-
icals), after which it was discarded, and PBS () was added. Finally,
the cells were observed under an Olympus FV500 confocal micro-
scope (Olympus, Tokyo). GJ activity was assessed using 6-CF dye
transfer, and the scraped edge was stained with DTMR.2.6. Cell viability assay
A total of 5.0 103 cells were seeded in a 96well plate. After 24 h
incubation, the cells were treated with 0.38e10 mM SU followed by
culturing for 24 h. Control cells were treatedwith 0.1% DMSO. At the
end of the period, 0.25 mg/mL MTT was added to each well and the
plate was incubated for 1 h. The supernatant was removed and
DMSO was added to each well. The absorbance at a wavelength of
540 nm and a referencewavelength of 650 nmwasmeasuredwith a
Multiscan JXmicroplate reader (Thermo Labsystems, Cheshire, UK).
Cell viability (%) was calculated as follows: [optical density (OD) of
the treated cells]/(OD of the control cells)  100.Fig. 1. The restoration of connexin 43 (Cx43) expression and gap junction (GJ) func-
tion. (A) Cx43 mRNA expression detected by real-time polymerase chain reaction
(PCR). Each bar represents the mRNA level normalized to the internal standard RPL32
and presented as an x-fold increase over H28 cells, and vertical lines indicate S.D. of
three independent experiments. **P < 0.01: Signiﬁcant difference between H28 and
H28-T cells by using the Aspin-Welch's t-test. (B) Cx43 protein expression detected by
western blotting. b-Actin is shown as the internal standard. (C) GJ function assessed by
scrape loading and dye transfer assay. 6-Carboxyﬂuorescein (6-CF) dye transfer (green)
was used to assess GJ function, the scraped edge was stained with dextran, tetrame-
thylrhodamine (DTMR) (red), and locations where 6-CF and DTMR overlapped are
shown in yellow (Merge). Bars represent 200 mm.2.7. Cell cycle analysis
A total of 1.5  105 H28 cells and 3.0  105 H28-T cells were
seeded in 60 mm dishes. After 6 h incubation, the cells were
cultured in medium containing 0.1% FBS for 24 h followed by
treatment with 10 mM SU for each indicated period. Control cells
were treated with 0.1% DMSO. Then, the cells were collected and
ﬁxed in 80% ethanol. Before analysis, the cells were incubated in
PBS () containing 50 mg/mL propidium iodide (Invitrogen) and
200 mg/mL RNaseA (MP Biomedicals, Santa Ana, CA, USA) for 30min
at 37 C. The cell suspension was ﬁltered through a nylon mesh
ﬁlter, and the ﬁltrate was analyzed using a BD FACSCanto™ II ﬂow
cytometer (BD Biosciences, San Jose, CA, USA).2.8. GJIC inhibition
Firstly, to determine the effect of GA on GJ activity, the cells were
treated with 40 mM GA or 0.1% DMSO for 24 h. Subsequently, GJ
activity was assessed by using the scrape loading and dye transfer
assay. Furthermore, to determine the effect of GJIC inhibition on SU
cytotoxicity, the cells were treated with 40 mMGA and 0.38e10 mM
SU for 24 h followed by assessment of cell viability by using the
MTT assay.
2.9. Short-interfering RNA (siRNA) transfection
A total of 2.2  105 H28-T cells were seeded in a 12 well plate.
After 6 h incubation, the cells were cultured in medium containing
0.1% FBS shortly before siRNA transfection using Lipofectamine®
3000 Reagent (Invitrogen), according to the manufacturer's pro-
tocol. The following siRNAs were used: a Bax-speciﬁc siRNA
(Hs_BAX_10); a negative control siRNA (AllStars Negative Control
Fig. 2. Sunitinib malate (SU) sensitivity of connexin 43 (Cx43)-transfected cells. Cells
were treated with the indicated concentrations of SU for 24 h, and cell viability was
assessed by MTT assay. Control cells (SU 0 mM) were treated with 0.1% dimethyl
sulfoxide (DMSO). Each bar represents the mean cell viability normalized to control in
each cell group, and vertical lines indicate S.D. of three independent experiments.
**P < 0.01, ***P < 0.001: Signiﬁcant difference between H28 and H28-T cells at each SU
concentration by using the Student's t-test or the Aspin-Welch's t-test.
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e2620siRNA). Both siRNAs were obtained from Qiagen (Valencia, CA,
USA). Cells were transfected with a ﬁnal concentration of 10 nM
siRNA for 24 h, and then used for western blotting and ﬂow
cytometry.2.10. Statistical analysis
Statistical analyseswere performed by using the Student's t-test,
the Aspin-Welch's t-test, or the TukeyeKramer test. A value of
P < 0.05 was considered statistically signiﬁcant.Fig. 3. Estimation of cell cycle distribution and apoptosis. Cells were treated with 10 mM su
ﬂow cytometry. Control cells (SU 0 mM) were treated with 0.1% dimethyl sulfoxide (DMSO). (
bar represents the mean percentage of cells in each population, and vertical lines indicate S
each cell group, þP < 0.05, þþP < 0.01, þþþP < 0.001: Signiﬁcant difference between H28 an
induction of apoptosis detected as the pre-G0-G1 (subG1 population) in cell cycle distributio
lines indicate S.D. of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001:
Signiﬁcant difference between H28 and H28-T cells treated with 10 mM SU by using the Tu3. Results
3.1. Cx43 expression is increased in conjunction with an increase in
GJ function induced by Cx43 gene transfection
Approximately, 13-fold increase over H28 cells in Cx43 mRNA
expression was detected in H28-T cells (Fig. 1A). Cx43 protein
expression was detected in H28-T cells, although no expression was
observed in H28 cells (Fig. 1B). Moreover, scrape loading revealed a
notable 6-CF dye transfer from the edge of the scraped area stained
with DTMR in H28-T cells (Fig. 1C). In contrast, only the periphery of
the scraped area was stained with 6-CF in H28 cells. These observa-
tions indicate the successful restoration of Cx43 expression and GJ
function in Cx43-transfected cells in comparison to their parent cells.3.2. Increased Cx43 expression enhances SU-induced cytotoxicity
It was conﬁrmed that H28 cells were resistant to SU; approxi-
mately, 80% of cells survived even after exposure to high concen-
trations of SU (Fig. 2). In contrast, the H28-T cell viability was lower
than that of H28 cells in the presence of SU. Speciﬁcally, less than
half of the control cells survived after exposure to 10 mM SU.3.3. Increased Cx43 expression induces S-phase arrest and
enhances SU-induced apoptosis
The S-phase population in H28-T cells was signiﬁcantly higher
than in H28 cells (Fig. 3A). SU had almost no effect on cell cycle dis-
tribution except for a signiﬁcant decrease in the S-phase population
in H28 cells when they were treated with SU for 24 h. SU increased
subG1 population, suggesting an increase in apoptotic population in
both types of cells (Fig. 3B). Notably, the rate of increase in subG1was
signiﬁcantly higher in H28-T cells than in H28 cells.nitinib malate (SU) for the indicated period, and each of 20,000 cells was analyzed by
A) Alteration in cell cycle distribution in H28 and H28-T cells in the presence of SU. Each
.D. of three independent experiments. *P < 0.05: Signiﬁcant difference from control in
d H28-T cells in each control by using the TukeyeKramer test. (B) Effect of SU on the
n. Each bar represents the mean percentage of cells in subG1 population, and vertical
Signiﬁcant difference from control in each cell group, and ##P < 0.01, ###P < 0.001:
keyeKramer test.
Fig. 4. Effect of sunitinib malate (SU) on receptor tyrosine kinase (RTK) signaling detected by western blotting. (A) Total expressions of vascular endothelial growth factor receptor 2
(VEGFR2) and platelet-derived growth factor b (PDGFRb) in naïve H28 and H28-T cells. Each bar represents the intensity of the protein bands normalized to the internal standard b-
actin, and vertical lines indicate S.D. of three independent experiments. (B) Total Akt (Akt) and phosphorylated Akt (p-Akt), and (C) total extracellular signal mediated receptor
kinases (ERK) and phosphorylated ERK (p-ERK) expressions after treatment with 10 mM sunitinib malate (SU) for each indicated period. Control cells (Cont) were treated with 0.1%
dimethyl sulfoxide (DMSO). Each bar represents the intensity of the protein bands normalized to the internal standard b-actin and presented as a ratio relative to 24 h control.
Vertical lines indicate S.D. of three independent experiments. **P < 0.01, ***P < 0.001: Signiﬁcant difference from control at each time point in each cell group by using the
TukeyeKramer test.
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extracellular signal-regulated kinase (ERK) activity and degradation
of Akt in the presence of SU
VEGFR2 and PDGFRb, which are the main targets of SU, were
expressed inboth,H28andH28-Tcells (Fig. 4A). The expression levels
of these receptors were not signiﬁcantly different between H28 and
H28-T cells. The effect of SU on Akt and ERK, which are downstream
factors of these receptors, was then investigated. Phosphorylation of
Akt was decreased after 24 h of SU treatment; this was followed by a
slight decrease of total expression of Akt after 48 h of SU treatment in
H28 cells, although these were not signiﬁcant changes (Fig. 4B). In
contrast, the total expression of Akt dramatically decreased in a time-
dependent manner and was associated with its decreased phos-
phorylation in H28-T cells. SU had no effect on both, total and
phosphorylated ERK expression in H28 cells (Fig. 4C). In H28-T cells,
phosphorylation of ERK signiﬁcantly decreased after 24 h of SUtreatment; this was followed by a slight decrease in the total
expression of ERK after 48 h of SU treatment.3.5. Enhancement of SU-induced cytotoxicity is independent of GJ
function
To investigate whether Cx43 enhances the antiproliferative
effect of SU through a GJ-dependent mechanism or not, GA (a GJ
inhibitor) was used. At ﬁrst, it was conﬁrmed that incubation
with 40 mM GA for 24 h resulted in the inhibition of GJ function
in H28-T cells (Fig. 5A). In contrast, no changes were observed
following GA treatment in H28 cells. When GA was combined
with SU, H28 cell viability was not altered as compared to
SU alone (Fig. 5B). GA had little effect on the cell viability of
H28-T in conjunction with low (3.3 mM or less) doses of SU,
although a signiﬁcant decrease in the cell viability was caused by
Fig. 5. Effect of gap junction (GJ) blockage on sunitinib malate (SU)-induced cytotoxicity. (A) GJ inhibition by a GJ inhibitor, 18b-glycyrrhetinic acid (GA). Cells were treated with
40 mM GA for 24 h, and scrape loading and dye transfer assay was performed. Control cells (Cont) were treated with 0.1% dimethyl sulfoxide (DMSO). 6-Carboxyﬂuorescein (6-CF)
dye transfer (green) was used to assess GJ function, scraped edge was stained with dextran, tetramethylrhodamine (DTMR) (red), and locations where 6-CF and DTMR overlapped
are shown in yellow (Merge). Bars represent 200 mm. (B) Effect of GA on the SU-induced cytotoxicity. Cells were treated with the indicated concentrations of SU and 40 mM GA
simultaneously for 24 h, and cell viability was assessed by MTT assay. Control cells (SU 0 mM) were treated with 0.1% DMSO. Each bar represents the mean cell viability normalized to
control in each cell group, and vertical lines indicate S.D. of three independent experiments. *P < 0.05, **P < 0.01: Signiﬁcant difference between GA-treated cells (with GA) and
untreated cells (without GA) at each SU concentration in each cell group by using the Student's t-test.
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e2622combined treatment with GA and 6 or 10 mM SU as compared to
SU alone.
3.6. Bax is potentially involved in the enhancement of SU-induced
cytotoxicity by Cx43
It has been demonstrated that the interaction between Cx43
and the proapoptotic factor Bax enhances gemcitabine-induced
apoptosis in pancreatic cancer cells (21). Thus, we investigated
whether Cx43 could interact with Bax in MM cells. As shown in
Fig. 6, Bax (23 kD) and Cx43 (43 kD) were immunoprecipitated
from the total cell lysates of SU-treated and untreated H28-T cells
by using an anti-Cx43 antibody or an anti-Bax antibody respec-
tively. Furthermore, the total Bax expression level was slightly
increased in H28-T cells than in H28 cells, although the difference
was not statistically signiﬁcant (Fig. 7A). SU had almost no effect
on total Bax expression level in both cells (Fig. 7B). However, a
cleaved Bax band, which is known as an active form of Bax, wasdetected only in the SU-treated H28-T cells. Then, knockdown of
Bax expression was performed; at ﬁrst, it was conﬁrmed that
treatment of Bax-speciﬁc siRNA efﬁciently suppressed Bax pro-
tein expression in H28-T cells (Fig. 8A). As expected, knockdown
of Bax expression reduced the rate of subG1 population when
they were treated with SU (Fig. 8C), although cell cycle distri-
bution was not affected (Fig. 8B). These results indicate that Bax is
activated by SU in H28-T cells, which contributes to the induction
of apoptosis.
4. Discussion
Agents that act upon speciﬁc molecular targets play a key role in
modern cancer chemotherapy. The phosphoinositide 3-kinase
(PI3K)/Akt pathway and the mitogen-activated protein kinase
(MAPK) pathway are known to be involved in the pathogenesis of
MM (22), and TKIs are thought to be promising agents for the in-
hibition of them. However, clinical treatment with TKIs such as
Fig. 6. Interaction between connexin 43 (Cx43) and Bax. Cells were treated with 10 mM
sunitinib malate (SU) for 24 h, and immunoprecipitation (IP) from H28-T cell extract
was performed using an anti-Cx43 antibody, an anti-Bax antibody or an anti-rabbit
antibody (negative control, NC) followed by western blotting (WB). Control cells
(Cont) were treated with 0.1% dimethyl sulfoxide (DMSO). (A) Bax was detected, and an
arrow represents its band. (B) Cx43 was detected, and each arrow represents a
phosphorylated (✤) and a non-phosphorylated (✤✤) form respectively. Each photo is a
representative of three independent experiments.
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e26 23sunitinib (SU) (19), geﬁtinib (23), and erlotinib (24) has failed
despite encouraging in vitro data. As one of the mechanisms of
resistance to TKIs, the activation of the bypass signaling pathway is
critical. For example,Welti et al. have reported that the inhibition ofFig. 7. Difference of Bax behaviors in H28 and H28-T cells detected by western blotting. (A)
the protein bands normalized to the internal standard b-actin, and vertical lines indicate S.D.
in H28 and H28-T cells. Cells were treated with 10 mM SU for 24 h. Control cells (Cont) were t
Arrows represent cleaved Bax bands. Each photo is a representative of three independent eﬁbroblast growth factor (FGF)-2 signaling reduces the resistance to
SU in endothelial cells (25). Exploration of molecules that enhance
the activity of TKIs in MM could lead to an improvement of MM
treatment.
The aim of this study was to evaluate the potential of Cx43, a
component of a type of intercellular channel called GJ, to enhance
the activity of SU in MM cells. Firstly, we prepared and character-
ized Cx43-transfected cells. It was shown that Cx43 mRNA and
protein expression levels were upregulated; this was associated
with the restoration of GJ function in H28-T (Cx43-transfected cells)
in comparison to the low Cx43 expression and GJ function observed
in H28 (their parental cells) as previously reported (11) (Fig. 1).
Subsequently, we assessed the difference in SU-induced cyto-
toxicity between H28 and H28-T cells. The cell viability test showed
that the cytotoxic effect of SUwas greater in H28-Tcells than in H28
cells (Fig. 2). In particular, the difference in cell viability was the
greatest in the presence of 10 mM SU. It was also observed that the
size of subG1 population in H28-T cells treated with 10 mM SU was
signiﬁcantly higher than in H28 cells (Fig. 3B). Treatment with low
concentrations of SU (3.3 mM or less) had no effect on the induction
of apoptosis and cell cycle distribution in both cells (data not
shown). On the basis of these results, it is assumed that the greatest
difference of cell viability between H28 and H28-T cells in the
presence of 10 mM SU was derived from the efﬁcient induction of
cell death in H28-T cells. Regarding cell cycle distribution, SU had
almost no inﬂuence except for the signiﬁcant increase in S-phase
population and the corresponding decrease in G1-phase population
after 24 h of SU treatment in H28 cells (Fig. 3A). Interestingly, when
the cell cycle population was compared between untreated H28
and H28-T cells, a signiﬁcantly higher S-phase population was
observed in H28-T cells than in H28 cells at every time point, which
was the same trend as our previous study (11). It should be further
investigated whether the S-phase increase inﬂuences SU sensitivity
or not in a future study.Total Bax expression in naïve H28 and H28-T cells. Each bar represents the intensity of
of three independent experiments. (B) Effect of sunitinib malate (SU) on Bax expression
reated with 0.1% dimethyl sulfoxide (DMSO). b-Actin is shown as the internal standard.
xperiments.
Fig. 8. Effect of Bax knockdown on SU-induced alteration in cell cycle distribution and
induction of apoptosis in H28-T cells. (A) Effect of siRNA treatment on Bax protein
expression. Cells were transfected with a ﬁnal concentration of 10 nM Bax-speciﬁc
siRNA (siBax) or negative control (NC) siRNA for 24 h, and protein expression was
detected by western blotting. b-Actin is shown as the internal standard. (B, C) Effect of
siRNA treatment on cell cycle distribution and induction of apoptosis detected as the
pre-G0-G1 (subG1 population) in cell cycle distribution in the presence of SU. Cells were
transfected with a ﬁnal concentration of 10 nM Bax-speciﬁc siRNA or NC siRNA for 24 h
followed by treatment with 10 mM sunitinib malate (SU) for 48 h. Control cells (SU
0 mM) were treated with 0.1% dimethyl sulfoxide (DMSO). Each of 20,000 cells was
analyzed by ﬂow cytometry. Each bar represents the mean percentage of cells in each
population, and vertical lines indicate S.D. of three independent experiments.
***P < 0.001: Signiﬁcant difference from control in each siRNA treatment group, and
###P < 0.001: Signiﬁcant difference between siBax and NC treated with 10 mM SU by
using the TukeyeKramer test.
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e2624Next, we assessed the effect of SU on RTK signaling. VEGFR2 and
PDGFRb were detected in both, H28 and H28-T cells (Fig. 4A).
VEGFR2 is the predominant isoform that mediates RTK signaling
among VEGFRs (26). PDGFRb is mainly expressed inMM cells, while
PDGFRa is expressed in both, MM and mesothelial cells (27). We
then investigated Akt, ERK, and their phosphorylated (active) form
expression e the downstream effectors of RTK signaling. In H28
cells, phosphorylation of Akt was inhibited by 24 h of SU treatment
with a subsequent decrease in total Akt expression (Fig. 4B). In
contrast, total Akt expression was almost undetectable in H28-T
cells after 24 h of SU treatment. This decrease in Akt expression
most likely occurs due to the induction of apoptosis, since it is
known that Akt is cleaved and inactivated by caspases during
apoptosis (28). Total and phosphorylated ERK expressions were not
altered by SU in H28 cells (Fig. 4C). In H28-T cells, phosphorylation
of ERK was inhibited by 24 h of SU treatment with a slight decrease
in total ERK expression following prolonged exposure. These results
indicate that increased Cx43 expression could enable SU to effec-
tively suppress RTK signaling. ERK is normally known as a regulator
of cell proliferation, and the activation of ERK signaling promotescell cycle progression from G1-to S-phase through upregulation of
cyclin D (29). It has been also reported that ERK signaling is regu-
lated by GJIC (30). Previously, we conﬁrmed that total and phos-
phorylated ERK expressions were higher in H28-T cells than in H28
cells (data not shown). Based on these ﬁndings, it is assumed that
the increased GJIC-activated ERK signaling resulted in a higher S-
phase population in H28-T cells than in H28 cells. In contrast, it has
been pointed out that sustained activation of ERK promotes
apoptosis (31). Liu et al. have shown that ERK increases the
expression of proapoptotic factors such as Bax and PUMA, through
p53 phosphorylation (32). In fact, total Bax expression was higher
in H28-T cells than in H28 cells (Fig. 7A), which could be related to
the rapid apoptotic process in H28-T cells exposed to SU.
Then, we investigated the mechanism by which Cx43 enhances
SU-induced cytotoxicity. As mentioned above, Cx appears to have
an inﬂuence on drug sensitivity of cancer cells through both, GJ-
dependent and GJ-independent mechanisms; the GJ-dependent
mechanism is known as a “bystander effect”. This is the effect
where the anticancer agent itself or a death signal is transmitted
throughout a tumor via GJ channels. The combination therapy of
ganciclovir and herpes simplex virus thymidine kinase working
through this effect is well documented, with a positive outcome
observed in a phase I clinical trial in malignant glioma (33).
Moreover, it has been shown that the restoration of GJ function
improves the antiproliferative effects of many kinds of agents,
including gemcitabine (34), cisplatin (35), and sorafenib (36). To
investigate whether GJ function is also involved in enhancing the
cytotoxic effect of SU, a pharmacological GJ inhibitor, 18b-glycyr-
rhetinic acid (GA) was used. GA inhibits GJ function by modulating
the phosphorylation status of Cx proteins leading to GJ disassembly
(37). It was veriﬁed that GJ function was inhibited by a 24 h of GA
treatment (Fig. 5A), although the inhibitory effect of GA is consid-
ered to be reversible (38). When the effect of GA on SU-induced
cytotoxicity was evaluated, no changes were observed in H28
cells, which had abnormal GJ function (Fig. 5B). The same result was
obtained in H28-T cells treated with low concentrations of SU. In
contrast, combined treatment with GA and high concentrations of
SU (6 mM and 10 mM) signiﬁcantly decreased H28-T cell viability in
comparison to SU alone. GJ normally contributes to maintaining
intracellular homeostasis, and it is believed that cell damage causes
transfer of survival signals or dilution of death signals through GJ
(39). In other words, GJ provides both, cell survival and cell death
signals, depending on the situation (40). In the present study, GJ is
considered to play a protective role against the cell damage that is
caused by high concentrations of SU; however, the details of this
mechanism remain to be elucidated.
We then explored the GJ-independentmechanism. It is assumed
that Cx43 modulates the expression or function of some pro or
antiapoptotic proteins, including Src (41), S-phase kinase associ-
ated protein (Skp) 2 (42), and Bax (21) in a GJ-independent manner.
In this work, the induction of apoptosis was notable, and we
focused on the proapoptotic factor Bax. In fact, Bax was conﬁrmed
to directly interact with Cx43 (Fig. 6). Cx43 is known to be a
phosphorylated protein, and both, phosphorylated and non-
phosphorylated forms are often detected (9). In Fig. 6B, both
bands were detected; however, it has not been elucidated which
form is important for the interaction with Bax. As shown in Fig. 7B,
cleaved Bax bands were detected in H28-T cells treated with SU,
although they were undetectable in H28 cells. This cleaved Bax has
been observed during drug-induced apoptosis (43). It is assumed
that Bax is cleaved by a calcium-activated cysteine protease, cal-
pain, in mitochondria (44) and that the cleaved form is a more
potent inducer of apoptosis as compared to the intact form (45,46).
Furthermore, the knockdown of Bax expression reduced the rate of
subG1 population in H28-T cells treated with SU, which indicates
M. Uzu et al. / Journal of Pharmacological Sciences 128 (2015) 17e26 25that Bax is partly involved in SU-induced apoptosis (Fig. 8). On the
basis of the results shown in Figs. 6, 7 and 8, it is possible that Cx43
could promote the cleavage and the activation of Bax through direct
interaction, which contributes to the efﬁcient induction of cell
death. In a future study, we aim to ascertain how Cx43 promotes
Bax activation.
In conclusion, we found that Cx43 could overcome the chemo-
resistance of H28 cells to SU in a GJ-independent manner. In this
study, Cx43-transfectant was used; however, it has been reported
that some chemical agents elevate endogenous Cx43 expression in
cancer cells, which contributes to enhance tumor suppressive effect
of anticancer agents (36,47). Thus, Cx43-targeted treatment will
help to establish a novel therapeutic strategy for chemotherapy
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